Medtronic's Integrated Diabetes System Makes The Grade In UK
This article was originally published in The Gray Sheet
Executive Summary
The United Kingdom’s National Health Service should adopt Medtronic’s MiniMed Paradigm Veo insulin pump/glucose monitor system over rival systems for patients with type 1 diabetes who experience disabling hypoglycemia, the country's National Institute for Health and Care Excellence recommends.
You may also be interested in...
Medtronic Launches Predictive MiniMed 640G Insulin Pump Outside The U.S.
The company touts the system as its latest breakthrough toward the development of an artificial pancreas. It can automatically suspend or resume insulin delivery based on pre-set thresholds.
FDA Approves Animas’ Vibe Linking Insulin Pump With DexCom CGM
The insulin pump is the first FDA-approved device featuring Dexcom’s G4 Platinum sensing technology; it allows patients to see glucose data and administer insulin directly from the pump.
Big Pharma CEOs Suggest Policy Changes As They Return To Beijing
Global CEOs of J&J, Pfizer, AbbVie and Takeda were among the top pharma executives attending the China Development Forum in its first in-person meeting in three years, and highlighted a number of pharma-related policy changes they would like to see in China. Meanwhile, a Japanese employee of Astellas has been detained in the country for alleged espionage.